VTAK - התחייבויות לטווח ארוך להון Catheter Precision Corporation

The Catheter Precision (VTAK) business relies on a narrow segment of arrhythmia-fighting software, which creates certain risks due to its dependence on US physicians. This price chart illustrates the trend of a metric that currently stands at 0.28. Catheter Precision (VTAK) develops robotic catheters, supplying them to Europe and the US to diversify its sales. Growth is driven by the implementation of the Amigo manipulator and the demand for the VIVO system.

The development of high-tech VIVO systems for cardiac surgery requires significant capital expenditures in R&D. This long-term debt-to-equity ratio reflects the proportion of borrowed funds with a maturity exceeding one year relative to equity. A decrease in this coefficient confirms financial autonomy, whereas its growth indicates the use of leverage. The balance of this metric determines the ability of Catheter Precision (VTAK) to scale innovations without the risk of default.